Exosomes are nano-sized vesicles ranging from 30-200nm that are present in eukaryotic fluids and facilitate a diverse range of cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells.
Because of their far ranging potential, exosomes can be commercialized as therapeutic agents, diagnostic tools, and cosmeceuticals. Today, a surging number of companies are developing exosome-based products and technologies.
Exosome Market Competitors
Currently, there are at least 45 market competitors which compose the exosome industry in therapeutics and diagnostics. Twenty six of them are companies specializing in exosomes and nineteen of them are established companies that have recently jumped into the exosome industry.
In the market analysis below, we present graphs and figures that elucidate key trends from across the exosome landscape. Particular emphasis is given to rates of exosomes papers and granted patents, as well as the rate at which competitors have entered the marketplace and their geographic distribution.
*Note: Right click on the images above to view them at full-size in a new window.
Industrial Landscape for Exosome Products and Technologies
In the slideshow below, we further analyze each of the exosome market competitors, presenting findings for each market competitor worldwide. We also reveal their individually issued patents.
*Note: Right click on the images above to view them at full-size in a new window.
As shown in the slideshow above, this downloadable PDF will include:
- Table 1. Born to be Exosome Companies (List of Exosome Companies)
- Table 2. Granted Patents from Exosome Companies
- Table 3. Companies Composing the Exosome Industry
Future Projections for the Exosome Industry
Substantial growth is expected for the exosomes market as these nano-vesicles gain momentum within existing applications and continue to get leveraged within emerging fields, such as liquid biopsy, precision medicine and regenerative medicine.
Globally, new market competitors are unlikely to surface in the near-term due to the global COVID-19 pandemic, but we anticipate that new market competition will emerge as the pandemic resolves.
Access the Original Files
Given the rapid rise of the global exosome industry and the strong demand we have had for this comprehensive market analysis completed by the BioInformant team, you can access the original files (13-page PPT and 10-page PDF) at this link for a limited-time only.
Richard Neubiser (formerly CellBGenix, GmbH (USA) says
Cade, good to see your reach into exosomes. I believe they they have the potential to be the “end all” some day. Your information is useful! Keep the momentum going forward.
Adam says
Have you heard of VITTI Labs?